Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021

COVID-19 vaccine effectiveness was evaluated in close contacts of cases diagnosed during January–April 2021. Among 20,961 contacts, 7,240 SARS-CoV-2 infections were confirmed, with 5,467 being symptomatic and 559 leading to hospitalisations. Non-brand-specific one and two dose vaccine effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Baz, Iván, Miqueleiz, Ana, Casado, Itziar, Navascués, Ana, Trobajo-Sanmartín, Camino, Burgui, Cristina, Guevara, Marcela, Ezpeleta, Carmen, Castilla, Jesús, Ibero Esparza, Carlos, Herranz, Mercedes, Arregui, Irati, Martín, Carmen, Polo, Isabel, Estévez, Ingrid, Tordoya, Igberto, Quílez, Delia, Lameiro, Francisco, Álvaro, Ana Isabel, López Moreno, Paula, Albéniz, Esther, Elía, Fernando, Gorricho, Javier, Ardanaz, Eva, Ascunce, Nieves, Arriazu, Maite, Baigorria, Fernando, Barricarte, Aurelio, de la Cruz, Enrique, Díaz, Jorge, Ederra, María, Egüés, Nerea, García Cenoz, Manuel, Iriarte, Nerea, Moreno-Iribas, Conchi, Sayón, Carmen, Vidán, Juana, Nuín, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161727/
https://www.ncbi.nlm.nih.gov/pubmed/34047271
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.21.2100438
Descripción
Sumario:COVID-19 vaccine effectiveness was evaluated in close contacts of cases diagnosed during January–April 2021. Among 20,961 contacts, 7,240 SARS-CoV-2 infections were confirmed, with 5,467 being symptomatic and 559 leading to hospitalisations. Non-brand-specific one and two dose vaccine effectiveness were respectively, 35% (95% confidence interval (CI): 25 to 44) and 66% (95% CI: 57 to 74) against infections, 42% (95% CI: 31 to 52) and 82% (95% CI: 74 to 88) against symptomatic infection, and 72% (95% CI: 47 to 85) and 95% (95% CI: 62 to 99) against COVID-19 hospitalisation. The second dose significantly increased effectiveness. Findings support continuing complete vaccination.

Ejemplares similares